 |
40 Products |  |
109 Diseases | | 40 Products |
|
37 Trials |  |
1900 News |  |
| «12...891011121314151617181920» |
- Euvax B (recombinant hepatitis B vaccine) / LG Chem
Enrollment closed: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Nov 17, 2016
P4, N=132, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting
- ||||||| ZemiStatin (gemigliptin/rosuvastatin FDC) / LG Chem
Trial completion, Combination therapy: Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE) (clinicaltrials.gov) - Oct 18, 2016
P3, N=290, Completed, Sponsor: LG Life Sciences
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| ficlatuzumab (AV-299) / LG Chem
Enrollment closed, Metastases: FOCAL: A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (clinicaltrials.gov) - Sep 30, 2016
P2, N=86, Active, not recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: TIVO-3: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Sep 23, 2016
P3, N=322, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2017 --> Aug 2018
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment closed, Enrollment change, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Sep 9, 2016
P1b, N=14, Active, not recruiting, Sponsor: James J Lee
Trial primary completion date: Dec 2017 --> Aug 2018 Recruiting --> Active, not recruiting | N=22 --> 14
- Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Phase classification, Surgery, Metastases: Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 17, 2016
P1b/2, N=49, Recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting | N=22 --> 14 Phase classification: P1/2 --> P1b/2
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Phase classification, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jul 28, 2016
P1b, N=22, Recruiting, Sponsor: Julie E. Bauman, MD, MPH
Phase classification: P1/2 --> P1b/2 Phase classification: P1 --> P1b
- Shinbaro (GCSB-5) / GC Pharma, LG Chem
Trial primary completion date: Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation (clinicaltrials.gov) - Jun 19, 2016
P=N/A, N=60, Recruiting, Sponsor: Jaseng Medical Foundation
Phase classification: P1 --> P1b Trial primary completion date: Apr 2016 --> Dec 2016
- |||||||||| Besivo (besifovir) / Gilead, LG Chem, Ildong
New P3 trial: Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues (clinicaltrials.gov) - Jun 9, 2016
P3, N=244, Recruiting, Sponsor: IlDong Pharmaceutical Co Ltd
- Euvax B (recombinant hepatitis B vaccine) / LG Chem
Trial primary completion date: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Jun 5, 2016
P4, N=132, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Apr 2016 --> Dec 2016 Trial primary completion date: Jun 2017 --> Dec 2017
- |||||| Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem
Enrollment open: A Study Comparing LBAL to Humira (clinicaltrials.gov) - May 20, 2016
P3, N=380, Recruiting, Sponsor: LG Life Sciences
Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- ||||| Euvax B (recombinant hepatitis B vaccine) / LG Chem
Enrollment closed, Enrollment change: Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. (clinicaltrials.gov) - May 20, 2016
P3, N=150, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting | N=393 --> 150
- |||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment open, Trial initiation date, Metastases: TIVO-3: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - May 19, 2016
P3, N=322, Recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Enrolling by invitation --> Active, not recruiting | N=393 --> 150 Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Apr 2016
- ||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Trial completion: Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin (clinicaltrials.gov) - May 18, 2016
P3, N=443, Completed, Sponsor: Sanofi
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Apr 2016 Active, not recruiting --> Completed
- ||||| MIT-001 / MitoImmune Therap
New P2 trial: Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients (clinicaltrials.gov) - May 12, 2016
P2, N=100, Recruiting, Sponsor: LG Life Sciences
- ZemiStatin (gemigliptin/rosuvastatin FDC) / LG Chem
Enrollment open: BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone (clinicaltrials.gov) - May 11, 2016
P1, N=37, Enrolling by invitation, Sponsor: LG Life Sciences
Active, not recruiting --> Completed Not yet recruiting --> Enrolling by invitation
- |||| MIT-001 / MitoImmune Therap
Trial completion: Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients (clinicaltrials.gov) - May 10, 2016
P2, N=60, Completed, Sponsor: LG Life Sciences
Not yet recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial suspension: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - May 6, 2016
P2, N=30, Suspended, Sponsor: Northwestern University
Active, not recruiting --> Completed Recruiting --> Suspended
- Gemiglo (gemigliptin) / Sanofi, LG Chem
Trial completion: Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=10, Completed, Sponsor: Seoul National University Hospital
Recruiting --> Suspended Not yet recruiting --> Completed
- |||||||||| Adalimumab BS MA (adalimumab biosimilar) / Mochida, LG Chem
New P3 trial: A Study Comparing LBAL to Humira (clinicaltrials.gov) - Apr 21, 2016
P3, N=380, Not yet recruiting, Sponsor: LG Life Sciences
- |||| cisplatin / Generic mfg.
Trial primary completion date: Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury (clinicaltrials.gov) - Apr 20, 2016
P2/3, N=182, Recruiting, Sponsor: Seoul National University Bundang Hospital
Not yet recruiting --> Completed Trial primary completion date: Oct 2015 --> Feb 2018
- Eutropin Plus (somatropin SR) / LG Chem, Bioton
Trial primary completion date: Efficacy and Safety Study of Sr-hGH in Comparison With Daily hGH in ISS Patients (clinicaltrials.gov) - Mar 24, 2016
P2, N=46, Completed, Sponsor: LG Life Sciences
Trial primary completion date: Oct 2015 --> Feb 2018 Trial primary completion date: Jul 2015 --> Mar 2015
- ||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Trial completion: A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study) (clinicaltrials.gov) - Mar 23, 2016
P3, N=132, Completed, Sponsor: LG Life Sciences
Trial primary completion date: Jul 2015 --> Mar 2015 Recruiting --> Completed
- |||||||||| TNFcept (etanercept biosimilar) / LG Chem, Mochida
New P3 trial: A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active RA Despite Methotrexate (MTX) (clinicaltrials.gov) - Mar 22, 2016
P3, N=165, Not yet recruiting, Sponsor: LG Life Sciences
- || Shinbaro (GCSB-5) / GC Pharma, LG Chem
Trial primary completion date, Adverse events: A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule (clinicaltrials.gov) - Mar 19, 2016
P=N/A, N=6700, Recruiting, Sponsor: Green Cross Corporation
Recruiting --> Completed Trial primary completion date: Dec 2015 --> Jun 2016
- Hyruan (sodium hyaluronate) / LG Chem
New trial: The Efficacy of Ultrasound-guided Hydrodilatation With Hyaluronic Acid for Patients With Adhesive Capsulitis (clinicaltrials.gov) - Mar 15, 2016
P=N/A, N=70, Recruiting, Sponsor: Taipei Veterans General Hospital, Taiwan
- || Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 10, 2016
P2, N=54, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Jan 2016 --> Jan 2017
- |||||||||| Euvax B (recombinant hepatitis B vaccine) / LG Chem
New P3 trial: Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine. (clinicaltrials.gov) - Mar 4, 2016
P3, N=393, Enrolling by invitation, Sponsor: Sanofi Pasteur, a Sanofi Company
- Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
Enrollment open, Trial initiation date, Trial primary completion date: PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes (clinicaltrials.gov) - Feb 26, 2016
P1, N=40, Recruiting, Sponsor: Gan and Lee Pharmaceuticals
Trial primary completion date: Jan 2016 --> Jan 2017 Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Dec 2015 | Trial primary completion date: Feb 2016 --> Jun 2016
- ||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Enrollment change: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Feb 18, 2016
P3, N=310, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Dec 2015 | Trial primary completion date: Feb 2016 --> Jun 2016 N=458 --> 310
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone (clinicaltrials.gov) - Feb 1, 2016
P1, N=25, Enrolling by invitation, Sponsor: LG Life Sciences
- | ZemiStatin (gemigliptin/rosuvastatin FDC) / LG Chem
New P1 trial: BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone (clinicaltrials.gov) - Feb 1, 2016
P1, N=40, Not yet recruiting, Sponsor: LG Life Sciences
- || Gemiglo (gemigliptin) / Sanofi, LG Chem
Enrollment closed, Trial primary completion date: An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=5180, Active, not recruiting, Sponsor: LG Life Sciences
N=458 --> 310 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date, Metastases: RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 25, 2016
P1/2, N=50, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Trial primary completion date: Jun 2014 --> Jun 2016
- ficlatuzumab (AV-299) / LG Chem
Biomarker, Trial initiation date, Trial suspension, Metastases: Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 19, 2016
P1, N=24, Suspended, Sponsor: Julie E. Bauman, MD, MPH
Trial primary completion date: Jun 2014 --> Jun 2016 Initiation date: Jan 2015 --> Sep 2015 | Not yet recruiting --> Suspended
- ficlatuzumab (AV-299) / LG Chem, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Enrollment open, Trial initiation date, Metastases: Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jan 19, 2016
P1, N=22, Recruiting, Sponsor: Julie E. Bauman, MD, MPH
Initiation date: Jan 2015 --> Sep 2015 | Not yet recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Aug 2015
- | Besivo (besifovir) / Gilead, LG Chem, Ildong
Trial completion: Bioequivalence Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers (clinicaltrials.gov) - Jan 15, 2016
P1, N=24, Completed, Sponsor: IlDong Pharmaceutical Co Ltd
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> Aug 2015 Not yet recruiting --> Completed
- ||||| TNFcept (etanercept biosimilar) / LG Chem, Mochida
Enrollment closed: A Study Comparing LBEC0101 to Enbrel (clinicaltrials.gov) - Jan 6, 2016
P3, N=372, Active, not recruiting, Sponsor: LG Life Sciences
Not yet recruiting --> Completed Recruiting --> Active, not recruiting
- Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
Trial completion, Trial primary completion date: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) - Dec 25, 2015
P1, N=350, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2015
- Euvax B (recombinant hepatitis B vaccine) / LG Chem
Enrollment open, Trial initiation date, Trial primary completion date: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Dec 12, 2015
P4, N=132, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Dec 2015 Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Nov 2015 | Trial primary completion date: Feb 2017 --> Jun 2017
- |||||||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P3 trial, Metastases: TIVO-3: A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Dec 11, 2015
P3, N=322, Not yet recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
- Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Trial primary completion date, Surgery, Metastases: Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 30, 2015
P1/2, N=49, Recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Recruiting | Initiation date: Aug 2015 --> Nov 2015 | Trial primary completion date: Feb 2017 --> Jun 2017 Trial primary completion date: Mar 2016 --> Mar 2017
- Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New trial, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Nov 21, 2015
P=N/A, N=70, Recruiting, Sponsor: Seoul National University Bundang Hospital
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial primary completion date: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Nov 10, 2015
P2, N=30, Recruiting, Sponsor: Northwestern University
Trial primary completion date: Mar 2016 --> Mar 2017 Trial primary completion date: Mar 2016 --> Mar 2017
- ||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Enrollment closed: Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin (clinicaltrials.gov) - Oct 28, 2015
P3, N=440, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Mar 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- ||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Enrollment closed: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Oct 27, 2015
P3, N=458, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment closed, Enrollment change, Metastases: Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) - Oct 20, 2015
P2, N=5, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=42 --> 5
- ||| MIT-001 / MitoImmune Therap
Enrollment closed, Trial primary completion date: Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients (clinicaltrials.gov) - Sep 18, 2015
P2, N=60, Active, not recruiting, Sponsor: LG Life Sciences
Recruiting --> Active, not recruiting | N=42 --> 5 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015
- ||||| DA-5202 - Dong / A
New P2 trial: Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee (clinicaltrials.gov) - Sep 18, 2015
P2, N=120, Recruiting, Sponsor: Dong-A ST Co., Ltd.
- ||||| ZemiStatin (gemigliptin/rosuvastatin FDC) / LG Chem
Enrollment closed, Trial primary completion date, Combination therapy: Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE) (clinicaltrials.gov) - Sep 15, 2015
P3, N=290, Active, not recruiting, Sponsor: LG Life Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2015 --> Mar 2016